Ashley E. Aaroe, M.D.

Peer-Reviewed Articles

1. Carriere, P, Haisraely, O, Aaroe, AE, Ahmed, K, Lewis, R, Colson-Fearon, D, Bolden, M, Swanson, T, Beckham, TH, Wang, C, De, BS, Perni, S, Tom, MC, Li, J, McGovern, SL, McAleer, MF, Ghia, AJ, Jiang, W, Chung, C, Grosshans, DR, Ballester, L, Esquenazi, Y, Kamiya Matsuoka, C, Yeboa, DN. Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology. Journal of neuro-oncology 179(1), 2026. e-Pub 2026. PMID: 42489814.
2. Avila EK, Reiner AS, Armstrong TS, Aaroe AE, Cunningham EM, Brown JG, Bruno F, Diarte J, Haggiagi A, Harrison RA, Joanta-Gomez A, Koekkoek JAF, Lee EQ, Le Rhun E, Miller H, Panageas KS, Peguero EN, Ruda R, Soffietti R, Templer JW, Tobochnik S, Vera E, Vogelbaum MA, Weller M, van den Bent M. RANO seizure working group-Tumor-Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice. Neuro Oncol 28(2):454-466, 2026. e-Pub 2026. PMID: 40650343.
3. Grippin, A, Marconi, C, Copling, S, Li, N, Braun, C, Rooney, M, Schrank, B, Gladish, G, Vaporciyan, AA, Johns, AC, Subbiah, IM, Aloia, TA, Wu, J, Wu, CC, Woodman, SE, Weinstein, JN, Tawbi, H, Shete, S, Scheet, PA, Ravi, V, Palaskas, NL, Nates, JL, Muthu, M, Musunuru, TN, McEnery, KW, Litton, J, John, TM, Jaffray, D, Hutcheson, KA, Gunther, J, Godoy, M, Futreal, A, French, KE, Draetta, G, Dabaja, BS, Crommett, JW, Cata, JP, Brock, K, Beird, H, Aaroe, AE, Lee, JJ, Sun, R, Sharma, P, Tran, HT, Zhang, J, Gibbons, DL, Wargo, J, Heymach, JV, Jiang, W, Lin, SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
4. Yeboa DN, Whitfield BT, Lin R, Ejezie CL, Swanson TA, Beckham TH, Wang C, De B, Perni S, Tom MC, Li J, McGovern SL, Harrison R, Majd NK, Puduvalli VK, Aaroe AE, Loghin M, O'Brien BJ, Patel AD, Patel CB, Wefel JS, Taslicay CA, Gule-Monroe M, Paulino AC, McAleer MF, Grosshans DR, Ghia AJ, Jiang W, Chung C, Maor M, Yang CH, Gubbiotti MA, Kamiya-Matsuoka C, Ballester LY, Weathers SP, Huse JT. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy. J Neurooncol 176(1):72, 2025. e-Pub 2025. PMID: 41191157.
5. Long JP, Prakash R, Jr PE, Knafl M, Lionel AC, Nair R, Ahmed S, Strati P, Malpica Castillo LE, Al-Zaki A, Chien K, Chihara D, Westin J, Khawaja F, Nastoupil LJ, Mulanovich V, Futreal A, Woodman SE, Daver NG, Flowers CR, Neelapu S, Manzano J, Iyer SP, Aaroe Ashley, Sanu A, Aloia Thomas A, Leend A, Badami Kiran K, Baganz Janna A, Pratibha B, Barbosa Gregory R, Beird Hannah C, Kristy B, Burton Elizabeth M, Juan C, Caroline C, Claussen Catherine M, John C, John CT, Michael C, Bouthaina D, Hiba D, Daniels Kevin M, Mary D, Giulio D, Jr EP, Sarah F, French Katy E, Andrew F, Maria G, Christopher G, Myrna G, Drew G, Jillian G, Kate H, David J, Jeff J, John Teny M, Trey K, Mark K, Anai K, Kwan Rayson C, Jack LJ, Jennifer L, McEnery Kevin W, Mary M, Benjamin M, Tejo M, Mayoora M, Joseph N, Owen Craig S, Priyadharshini P, Nicholas P, Patel Jay J, Sabitha P, Lucas R, Vinod R, Cristhiam RH, Bilja S, Scheet Paul A, Stephanie S, Shaw Kenna R, Sanjay S, Shoenthal Daniel P, Stoltenberg Lessley J, Ishwaria S, Hussein T, Phillip T, Anastasia T, Samir U, Benju V, Weber Max C, John W, Eric WS, Wozny Mark C, Carol W, Jia W, Yao James C, Chingyi Y, Emily Y, Steven Z. Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy. JAMA Netw Open , 2025. e-Pub 2025. PMID: 40193078.
6. Lam K, Nasr LF, Andersen CR, Marqueen KE, Li J, Wang C, Beckham TH, Majd NK, Aaroe AE, Loghin M, O'Brien BJ, McGovern SL. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors. Adv Radiat Oncol 10(2):101697, 2025. e-Pub 2025. PMID: 39866593.
7. Pham, L, Weller, L, Gann, CN, Schumacher, K, Vlassak, S, Swanson, T, Highsmith, KN, O’Brien, BJ, Nash, S, Aaroe, AE, De Groot, J, Majd, NK. Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. Oncologist 30(1), 2025. e-Pub 2025. PMID: 38815166.
8. Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O'Brien BJ, Majd NK, Loghin ME, Patel CB, Weathers SP, Puduvalli VK, Kamiya-Matsuoka C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study. Neurooncol Pract 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
9. Simbaqueva C, Aaroe AE, Rubio D, Loghin M, Treiber J, Ballester L, Fuller G, Gopakumar S, Kim Betty YS, Suarez-Almazor. Leptomeningeal Immunoglobulin G4–Related Disease: A Case Report. Annals of Internal Medicine: Clinical Cases 2(12), 2023. e-Pub 2023.
10. Aaroe A, Kurzrock R, Goyal G, Goodman AM, Patel H, Ruan GJ, Ulaner G, Young JR, Li Z, Dustin D, Go RS, Diamond EL, Janku F. Successful Treatment of Non-Langerhans Cell Histiocytosis with the MEK Inhibitor Trametinib: A Multicenter Analysis. Blood Adv 7(15):3984-3992, 2023. e-Pub 2023. PMID: 36857436.
11. Reddy, DS, Cuenca, JA, Botdorf, JS, Muthu, M, Hanmandlu, A, Wegner, RC, Crommett, JW, Gutierrez, C, Rathi, N, Sajith, B, Knafl, M, Abbas, HA, Woodman, SE, Nates, JL, Aaroe, AE, Aloia, TA, Andrews, L, Badami, KK, Baganz, JA, Bajwa, P, Baker, LR, Barbosa, GR, Beird, H, Bourgeois, M, Brock, K, Burton, EM, Cata, JP, Chung, C, Cutherell, M, Dabaja, BS, Draetta, G, French, KE, Futreal, A, Gibbons, C, Godoy, M, Gunther, J, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Palaskas, NL, Ravi, V, Scheet, PA, Schmidt, S, Subbiah, IM, Tawbi, H, Wu, J, Yao, JC. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clinic Proceedings 98(3):451-457, 2023. e-Pub 2023. PMID: 36868753.
12. Michaelson NM, Aaroe AE, Lewis SL, Safdieh JE. Emerging Subspecialties in Neurology: Becoming an Editor-In-Chief. Neurology 97(20):e2046-e2049, 2021. e-Pub 2021. PMID: 34376514.
13. Aaroe AE, Glitza Oliva IC, Al-Zubidi N, Nader ME, Kaya D, Ferguson SD, Wang C, Fuller G, Harrison RA. Pearls & Oy-sters: Primary Pineal Melanoma With Leptomeningeal Carcinomatosis. Neurology 97(5):248-250, 2021. e-Pub 2021. PMID: 33931525.
14. Kummer BR, Diaz I, Wu X, Aaroe AE, Chen ML, Iadecola C, Kamel H, Navi BB. Associations between cerebrovascular risk factors and parkinson disease. Ann Neurol 86(4):572-581, 2019. e-Pub 2019. PMID: 31464350.

Review Articles

1. Mohammed C, Aaroe AE, Buchold G, Krummel DAP, Stamets P, Sharma A, Alschuler L, Sengupta S. Fungal-derived supplements in integrative oncology. Am J Med 139(4):530-537, 2026. e-Pub 2026. PMID: 41534686.
2. Rong J, Jafri F, Ngo S, Chatterjee A, Moura Nascimento Santos MJ, Garza D, Salim H, Aaroe AE, Menon R, Mortan R, Urias Rivera AC, Zhang HC, Patel A, Rojas Hernandez C, Jeff Li Y, Sheshadri A, Shariff A, Schneider B, Thomas A, Wang Y. Rare irAEs associated with immune checkpoint inhibitor therapy. Expert Opin Drug Saf, 2026. e-Pub 2026. PMID: 41664562.
3. Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15:1447021, 2024. e-Pub 2024. PMID: 39247203.
4. Alsalem AN, Scarffe LA, Briemberg HR, Aaroe AE, Harrison RA. Neurologic Complications of Cancer Immunotherapy. Curr Oncol 30(6):5876-5897, 2023. e-Pub 2023. PMID: 37366923.
5. Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv 5(1):vdad009, 2023. e-Pub 2023. PMID: 36968288.
6. Aaroe AE, Nevel KS. Central Nervous System Involvement of Natural Killer and T Cell Neoplasms. Curr Oncol Rep 21(5):40, 2019. e-Pub 2019. PMID: 30919085.

Abstracts

1. Drakaki A, Kurian M, Mar N, Bupathi M, Nizam A, Ahmad H, Bangs R, Aaroe A, Habib A, Lloyd J, Custodio C, Decewicz D, Harrison M, Halabi AA. Consensus guidance on early identification and management of peripheral neuropathy in patients with UC receiving enfortumab vedotin: A Delphi study. Journal of Clinical Oncology, 2026. e-Pub 2026.
2. Thomas Z, Jiang CY, Speck P, Moussa MJ, Crupi E, Gao J, Desai MD, Shah AY, Goswami S, Siefker-Radtke AO, Johns A, Glover M, Logothetis C, Msaouel P, Aaroe A, Patel AB, Campbell MT, Alhalabi AO. Correlation of adverse events (AEs) and clinical outcomes in first-line enfortumab vedotin–pembrolizumab (EVP) treatment for locally advanced or metastatic urothelial cancer (La/mUC). Journal of Clinical Oncology, 2026. e-Pub 2026.
3. Murray, J, Nair, S, Yepez Gonzalez, P, Choi, J, Aaroe, AE, Gutierrez, C, Hsu, S. INTRACRANIAL HEMORRHAGE IN CANCER PATIENTS: CLINICAL CHARACTERISTICS AND OUTCOMES IN ONCOLOGIC ICU. Critical care medicine 54(3), 2026. e-Pub 2026.
4. Chen L, Ostos-Mendoza KC, Alhalabi O, Aparicio A, Araujo JC, Campbell MT, Corn PG, Desai M, Gao J, Goswami S, Hahn AW, Jana B, Jonasch E, Kovitz CA, Lin JK, Msaouel PM, Pilie P, Shah AY, Sharma P, Siefker-Radtke AO, Tannir NM, Zurita AJ, Wang J, Rawther-Karedath A, Wang E, Hosing C, Sheth RA, Lu H, Aaroe A, Logothetis C, Palaskas N, Siddiqui BA, Subudhi SK. Early targeted biologics are associated with improved clinical outcomes in immune-related myocarditis, myositis, and myasthenia gravis. Journal for ImmunoTherapy of Cancer, 2025. e-Pub 2025.
5. Jad TM, Cindy J, Sheeba V, Anishia R, Hongchao H, Saivaroon G, Emanuele C, Zachariah T, Amishi S, Andrew H, Nizar T, Pavlos M, Sumit S, Bilal S, Matthew C, Ashley A, Omar A. Clinical and prognostic characterization of high-grade neurologic immune-related adverse events in patients with urinary cancers. Journal for ImmunoTherapy of Cancer, 2024. e-Pub 2024.
6. Majd, NK, Yeboa, DN, Wang, S, Weathers, S, Yuan, Y, Al Anssari, H, Kamiya Matsuoka, C, O'Brien, BJ, Aaroe, AE, Patel, C, Dagher, SA, Wintermark, M, Ferguson, SD, Puduvalli, VK, Liu, SJ, Raleigh, D, de Groot, JF. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. Journal of Clinical Oncology 42(16_suppl):2076, 2024. e-Pub 2024.
7. Gajagowni S, Rawther-Karedath A, Varughese S, Ren W, Alhalabi O, Campbell MT, Gubbiotti M, Lawson B, Lu H, Aaroe A, Woodman K, Bhattacharjee M, Sheth RA, Subudhi SK, Siddiqui BA. Core needle biopsy for diagnosis of immune-mediated myositis. Journal for ImmunoTherapy of Cancer, 2023. e-Pub 2023.
8. Conley A, Li L, Livingston JA, Bishop A, Grosshans D, Ghia A, Grace M, Khanduri I, Lang W, Bird J, Alvarez-Breckeridge C, Raza S, Rhines L, DeMonte F, Lazar A, Wang WL, Aaroe A, Lin H, Roszik J, Amini B, Yevich S, Levy J, Sommer J, Freed D, Akdemir KC, Puduvalli V, Patel S. A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA. Abstract presentation at Connective Tissue Oncology Society Annual Meeting 2021, 2022. e-Pub 2022.
9. Pham L, Gann C, Schumacher K, Vlassak S, Swanson T, Highsmith K, Ou A, Clarke N, Aaroe AE, Robell L, O’Brien B, Nash S, DeGroot JD, Majd N. Complete Response to Adjuvant Teopotinib in a Patient with Newly Diagnosed disseminated Glioblastoma (GBM) Harboring MET Amplification. Poster presentation at Society for Neuro-Oncology Annual Meeting, 2021. e-Pub 2021.
10. Aaroe AE, Tummala S. Fixed ptosis as a symptom of myositis secondary to checkpoint inhibition. Poster presentation at Society for Neuro-Oncology Annual Meeting, 2021. e-Pub 2021.
11. Aaroe AE, Sarkar S, Sherani S, McAleer M, Fuller G, Zaky W. SHH-driven medulloblastoma with concurrent unilateral renal agenesis. Poster presentation at Society for Neuro-Oncology Pediatric Neuro-Oncology Research Conference, 2021. e-Pub 2021.
12. Aaroe AE, Ou A, McGovern S, Paulino A, Johnson J, Huse J, Fuller G, de Groot J, Walter A, Zaky W. Diffuse leptomeningeal glioneuronal tumor: a case series. Poster presentation at Society for Neuro-Oncology Pediatric Neuro-Oncology Research Conference, 2021. e-Pub 2021.
13. Aaroe AE, Glitza Oliva IC, Nader ME, Kaya D, Ferguson S, Wang C, Fuller G, Harrison RA, Al-Zubidi N. Primary Pineal Melanoma with Leptomeningeal Carcinomatosis. Poster Presentation at North American Neuro-Ophthalmology Society Meeting, 2021. e-Pub 2021.
14. Aaroe AE, Team D, Harrison R, Majd N, O’Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Yung WK, de Groot J, Woodman K. A snapshot of the impact of COVID-19 on patients with nervous system tumors. Poster Presentation at Society for Neuro-Oncology Annual Meeting 2020 and MD Anderson Brain Tumor Center Scientific Retreat 2020, 2020. e-Pub 2020.
15. Aaroe AE, Dono A, Youssef M, Alfaro-Munoz K, Liao E, Weathers S, O’Brien B, Majd N, Harrison R, Loghin M, Soomro Z, Williford G, Fuller G, Yung WK, Yeboa D, Esquenazi Y, Ballester L, de Groot J, Kamiya-Matsuoka C. A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma. Poster Presentation at Society for Neuro-Oncology Annual Meeting, 2020. e-Pub 2020.
16. Aaroe AE, Alfaro-Munoz K, Bornstein C, Chen M, Woodman K, Tummala S, Kleiman A, de Groot J, Loghin M. A retrospective single-center experience with nonbacterial thrombotic endocarditis and stroke - outcomes, anticoagulation strategies, and incorporation of next-generation sequencing data. Poster Presentation at Society for Neuro-Oncology Annual Meeting, 2020. e-Pub 2020.
17. Kummer BR, Aaroe AE, Kamel H, Iadecola C, Navi B. Associations between Parkinson Disease and Stroke. Poster Presentation at American Academy of Neurology Annual Meeting, 2017. e-Pub 2017.
18. Blizinsky K, Aaroe AE, Gejman P, Sanders A, Duan J, Penzes P, Wang L. A novel bioinformatic approach for the identification of CNV risk elements: application to 16p11.2 structural rearrangements in schizophrenia. Poster Presentation at International Congress on Schizophrenia Research, 2012. e-Pub 2012.
19. Ospina Romero M, Aaroe AE, Ballester L, Gubbiotti M. Clinicopathological and Molecular Characteristics of IDH-Wildtype Glioblastoma with FGFR3::TACC3 Fusion. American Association of Neuropathologists.
20. Matcheswalla S, Check R, Aaroe A, Chen M. Immune Checkpoint Inhibitor Induced Parkinsonism and Breakthrough Seizures in Medically Refractory Epilepsy: A Case Report. American Academy of Neurology.
21. Avva S, Suha G, Aaroe AE. Mollaret-Like Recurrent Aseptic Meningitis in a Lymphoma Survivor with Negative HSV Testing. AAN Autoimmune Neurology Conference.
22. Aaroe AE, Patel Rutu. Investigating the Relationship Between Multiple Lymphomas and Relapsing Parsonage-Turner Syndrome - A Case Study. AAN Autoimmune Neurology.
23. Aaroe AE, Oguejiofor A, Khampara S. Combined Central and Peripheral Nervous System Demyelination. AAN Autoimmune Neurology Conference.
24. Touat M, Cloughesy TF, Ren X, Lopez J, Wu J, McBain C, la Fuente MID, Sepulveda JM, Ducray F, Geurts M, Peters KB, Vieito M, Aaroe A, Blumenthal DT, Bumes E, Bunse L, Chong RA, Larrieu D, Narita Y, Rudà R, Saito R, Wick A, Chukwueke U, Ebiana V, Hassan I, Man A, Abshire M, Knipstein J, Mellinghoff IK, Wen PY. Safety outcomes from Phase 1b/2 study of vorasidenib in combination with temozolomide in patients with high-grade mutant IDH1 or IDH2 glioma (IDHEAL-4U). Society for Neuro-Oncology Annual Meeting.

Book Chapters

1. Pina Y, Aaroe AE, Forsyth P, Gatewood T, Glitza Oliva IC. Intrathecal treatments for leptomeningeal metastases. In: Cerebrospinal Fluid and Subarachnoid Space Pathology and Disorders: Volume 2. Elsevier, 2022.
2. Weathers SP, O'Brien B, Aaroe AE, Yeboa DN, Prabhu S, de Groot JF. Tumors of the Central Nervous System. In: The MD Anderson Handbook of Medical Oncology. 4. McGraw Hill, 2022.
3. Aaroe AE, Henchcliffe C. Promises and challenges of MSC-based therapies: Parkinson's Disease and Parkinsonism. In: A Roadmap to Non-hematopoietic Stem Cell-Based Therapeutics: from the bench to the clinic. Academic Press, 2018.
4. Aaroe AE. Altered Mental Status and Syncope. In: Oncology Hospital Medicine: A Guide for Frontline Clinicians.

Letters to the Editor

1. Aaroe AE, Majd N, Weathers SP, de Groot JF. Potential neurologic and oncologic implications of the novel coronavirus. Neuro Oncol 22: 1050-1051, 2020.

Web Publications

1. Aaroe AE. Neurology on the Hill: My Role as an Advocate for Neurology.